Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Clinical and Translational Oncology
Published in: Clinical and Translational Oncology 2/2018

01-02-2018 | Research Article

Clinicopathologic parameters associated with postoperative complications and risk factors for tumor recurrence and mortality after tumor resection of patients with colorectal cancer

Authors: Z. Bai, J. Wang, T. Wang, Y. Li, X. Zhao, G. Wu, Y. Yang, W. Deng, Z. Zhang

Published in: Clinical and Translational Oncology | Issue 2/2018

Login to get access

Abstract

Objective

To delineate the association of postoperative complications with clinicopathologic factors and to identify risk factors for tumor recurrence and mortality after tumor resection in patients with colorectal cancer (CRC).

Methods

The clinical data of 1144 patients with CRC who underwent surgical intervention between 2003 and 2013 were retrieved. Correlations of postoperative complications with clinicopathologic factors were examined using univariate analysis. Risk factors for tumor recurrence and mortality of the patients after tumor resection were identified using multivariate Cox proportional hazards models. Time to relapse and overall survival were analyzed using log-rank test of Kaplan–Meier analysis.

Results

Blood carcinoembryonic antigen (CEA) significantly correlated with early symptoms, preoperative manifestations, and tumor pathology. Low differentiation grade of tumor increased the risk of recurrence after surgery in all patients with CRC. In the same cohort of patients, elevated blood CEA, low differentiation grade of tumor, laparotomy, smoking history, and TNM stage IV and III increased the mortality risk after tumor resection. In patients with advanced colon cancer, risk for postoperative mortality was increased by blood CEA, advanced tumor stage, and low tumor differentiation grade; while in those with advanced rectal cancer, blood CEA, pathologic type other than mucinous/adenocarcinoma, and laparotomy were identified as significant risk factors. In both groups of patients, postoperative chemotherapy significantly reduced the risk of mortality.

Conclusions

The present work has identified clinical factors increasing the risk of recurrence as well as mortality after surgery in more than 1,000 patients with CRC. Postoperative chemotherapy is associated with a significant reduction in the risk of mortality. All of these findings should provide insights into the better management of critically ill patients with CRC.
Literature
1.
2.
Vogelstein B, Fearon ER, Hamilton SR, Kern SE, Preisinger AC, Leppert M, et al. Genetic alterations during colorectal-tumor development. N Engl J Med. 1988;319(9):525–32.CrossRefPubMed
3.
Sameer AS, Parray FQ, Dar MA, Nissar S, Banday MZ, Rasool S, et al. Cyclin D1 G870A polymorphism and risk of colorectal cancer: a case control study. Mol Med Rep. 2013;7(3):811–5.CrossRefPubMed
4.
5.
Lasry A, Zinger A, Ben-Neriah Y. Inflammatory networks underlying colorectal cancer. Nat Immunol. 2016;17(3):230–40.CrossRefPubMed
6.
Housseau F, Wu S, Wick EC, Fan H, Wu X, Llosa NJ, et al. Redundant innate and adaptive sources of IL-17 production drive colon tumorigenesis. Cancer Res. doi:10.​1158/​0008-5472.​CAN-15-0749 (2016e-pub ahead of print Feb 15).
7.
DeSantis CE, Lin CC, Mariotto AB, Siegel RL, Stein KD, Kramer JL, et al. Cancer treatment and survivorship statistics, 2014. CA Cancer J Clin. 2014;64(4):252–71.CrossRefPubMed
8.
Siegel R, Desantis C, Jemal A. Colorectal cancer statistics, 2014. CA Cancer J Clin. 2014;64(2):104–17.CrossRefPubMed
9.
Sweetser S, Jones A, Smyrk TC, Sinicrope FA. Sessile serrated polyps are precursors of colon carcinomas predominantly with deficient DNA mismatch repair. Clin Gastroenterol Hepatol. doi:10.​1016/​j.​cgh.​2016.​01.​021 (2016e-pub ahead of print Feb 16).
10.
Sinicrope FA, Okamoto K, Kasi PM, Kawakami H. Molecular biomarkers in the personalized treatment of colorectal cancer. Clin Gastroenterol Hepatol. doi:10.​1016/​j.​cgh.​2016.​02.​008 (2016e-pub ahead of print Feb 9).
11.
Ruibal Morell A. CEA serum levels in non-neoplastic disease. Int J Biol Mark. 1992;7(3):160–6.
12.
Sorensen CG, Karlsson WK, Pommergaard HC, Burcharth J, Rosenberg J. The diagnostic accuracy of carcinoembryonic antigen to detect colorectal cancer recurrence—a systematic review. Int J Surg. 2016;25:134–44.CrossRefPubMed
13.
Basu A, Seth S, Chauhan AK, Bansal N, Arora K, Mahaur A. Comparative study of tumor markers in patients with colorectal carcinoma before and after chemotherapy. Ann Transl Med. 2016;4(4):71.PubMedPubMedCentral
14.
Ikeguchi M, Ashida K, Saito H. New prognostic indicator is useful for predicting the survival of patients with unresectable advanced colorectal cancer. Hepatogastroenterology. 2015;62(140):859–62.PubMed
15.
Eren T, Burcu B, Tombalak E, Ozdemir T, Leblebici M, Ozemir IA, et al. Clinical significance of the glasgow prognostic score for survival after colorectal cancer surgery. J Gastrointest Surg. doi:10.​1007/​s11605-016-3114-2 (2016e-pub ahead of print Feb 29).
16.
17.
Pecorelli N, Amodeo S, Frasson M, Vignali A, Zuliani W, Braga M. Ten-year outcomes following laparoscopic colorectal resection: results of a randomized controlled trial. Int J Colorectal Dis. doi:10.​1007/​s00384-016-2587-5 (2016e-pub ahead of print Apr 18).
18.
Patankar SK, Larach SW, Ferrara A, Williamson PR, Gallagher JT, DeJesus S, et al. Prospective comparison of laparoscopic vs. open resections for colorectal adenocarcinoma over a ten-year period. Dis Colon Rectum. 2003;46(5):601–11.CrossRefPubMed
19.
Braga M, Pecorelli N, Frasson M, Vignali A, Zuliani W, Carlo VD. Long-term outcomes after laparoscopic colectomy. World J Gastrointest Oncol. 2011;3(3):43–8.CrossRefPubMedPubMedCentral
20.
O’Connell MJ, Campbell ME, Goldberg RM, Grothey A, Seitz JF, Benedetti JK, et al. Survival following recurrence in stage II and III colon cancer: findings from the ACCENT data set. J Clin Oncol. 2008;26(14):2336–41.CrossRefPubMed
21.
Kobayashi H, Mochizuki H, Sugihara K, Morita T, Kotake K, Teramoto T, et al. Characteristics of recurrence and surveillance tools after curative resection for colorectal cancer: a multicenter study. Surgery. 2007;141(1):67–75.CrossRefPubMed
Metadata
Title
Clinicopathologic parameters associated with postoperative complications and risk factors for tumor recurrence and mortality after tumor resection of patients with colorectal cancer
Authors
Z. Bai
J. Wang
T. Wang
Y. Li
X. Zhao
G. Wu
Y. Yang
W. Deng
Z. Zhang
Publication date
01-02-2018
Publisher
Springer International Publishing
Published in
Clinical and Translational Oncology / Issue 2/2018
Print ISSN: 1699-048X
Electronic ISSN: 1699-3055
DOI
https://doi.org/10.1007/s12094-017-1708-0

Other articles of this Issue 2/2018

Clinical and Translational Oncology 2/2018 Go to the issue

Research Article

MRI-guided radiotherapy for head and neck cancer: initial clinical experience

Research Article

Adjuvant versus salvage radiotherapy in prostate cancer: multi-institutional retrospective analysis of the Spanish RECAP database

Review Article

Key points to optimizing management and research on cancer-associated thrombosis

Review Article

Management of unresectable, locally advanced pancreatic adenocarcinoma

Research Article

Long-term clinical benefit from salvage EGFR tyrosine kinase inhibitors in advanced non-small-cell lung cancer patients with EGFR wild-type tumors

Research Article

Treatment strategies for rectal cancer with synchronous liver metastases: surgical and oncological outcomes with propensity-score analysis
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits